Fan Fan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fan Fan has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Hao Zhang
Hypothalamic Pituitary Research Centre, Xiangya Hospital, Central South University, Changsha, P. R. China
2 shared publications- Quan Cheng
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China
2 shared publications Ruizhe Wang
Department of Urinary Surgery, Xiangya Hospital, Central South University, Changsha, China
2 shared publications- Zhixiong Liu
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China
2 shared publications - Anliu Tang
Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, China
1 shared publication Chunrun Qu
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, P. R. China
1 shared publication
Latest Publications
- Open Access
- 11 September 2024
- Published by Springer Nature in Journal of Big Data
- Vol. 11 (1) , 1-22
Inhibitory neuron links the causal relationship from air pollution to psychiatric disorders: a large multi-omics analysis
Psychiatric disorders are severe health challenges that exert a heavy public burden. Air pollution has been widely reported as related to psychiatric disorder risk, but their casual association and pathological mechanism remained unclear. Herein, we systematically investigated the large genome-wide association studies (6 cohorts with 1,357,645 samples), single-cell RNA (26 samples with 157,488 cells), and bulk-RNAseq (1595 samples) datasets to reveal the genetic causality and biological link between four air pollutants and nine psychiatric disorders. As a result, we identified ten positive genetic correlations between air pollution and psychiatric disorders. Besides, PM2.5 and NO2 presented significant causal effects on schizophrenia risk which was robust with adjustment of potential confounders. Besides, transcriptome-wide association studies identified the shared genes between PM2.5/NO2 and schizophrenia. We then discovered a schizophrenia-derived inhibitory neuron subtype with highly expressed shared genes and abnormal synaptic and metabolic pathways by scRNA analyses and confirmed their abnormal level and correlations with the shared genes in schizophrenia patients in a large RNA-seq cohort. Comprehensively, we discovered robust genetic causality between PM2.5, NO2, and schizophrenia and identified an abnormal inhibitory neuron subtype that links schizophrenia pathology and PM2.5/NO2 exposure. These discoveries highlight the schizophrenia risk under air pollutants exposure and provide novel mechanical insights into schizophrenia pathology, contributing to pollutant-related schizophrenia risk control and therapeutic strategies development. Graphical Abstract
- 11 September 2024
- Published by Springer Nature in Journal of Big Data
- Vol. 11 (1) , 1-22
Open AccessInhibitory neuron links the causal relationship from air pollution to psychiatric disorders: a large multi-omics analysis
Psychiatric disorders are severe health challenges that exert a heavy public burden. Air pollution has been widely reported as related to psychiatric disorder risk, but their casual association and pathological mechanism remained unclear. Herein, we systematically investigated the large genome-wide association studies (6 cohorts with 1,357,645 samples), single-cell RNA (26 samples with 157,488 cells), and bulk-RNAseq (1595 samples) datasets to reveal the genetic causality and biological link between four air pollutants and nine psychiatric disorders. As a result, we identified ten positive genetic correlations between air pollution and psychiatric disorders. Besides, PM2.5 and NO2 presented significant causal effects on schizophrenia risk which was robust with adjustment of potential confounders. Besides, transcriptome-wide association studies identified the shared genes between PM2.5/NO2 and schizophrenia. We then discovered a schizophrenia-derived inhibitory neuron subtype with highly expressed shared genes and abnormal synaptic and metabolic pathways by scRNA analyses and confirmed their abnormal level and correlations with the shared genes in schizophrenia patients in a large RNA-seq cohort. Comprehensively, we discovered robust genetic causality between PM2.5, NO2, and schizophrenia and identified an abnormal inhibitory neuron subtype that links schizophrenia pathology and PM2.5/NO2 exposure. These discoveries highlight the schizophrenia risk under air pollutants exposure and provide novel mechanical insights into schizophrenia pathology, contributing to pollutant-related schizophrenia risk control and therapeutic strategies development. Graphical Abstract
- 1 March 2021
- Published by Elsevier in Cancer Letters
- Vol. 500, 87-97
A novel integrated system using patient-derived glioma cerebral organoids and xenografts for disease modeling and drug screening
- 1 March 2021
- Published by Elsevier in Cancer Letters
- Vol. 500, 87-97
A novel integrated system using patient-derived glioma cerebral organoids and xenografts for disease modeling and drug screening
- Top Cited PapersOpen Access
- 1 April 2020
- Published by Elsevier in Cancer Letters
- Vol. 476, 1-12
Immunotherapy for glioma: Current management and future application
- 1 April 2020
- Published by Elsevier in Cancer Letters
- Vol. 476, 1-12
Top Cited PapersOpen AccessImmunotherapy for glioma: Current management and future application
- 1 November 2019
- Published by Elsevier in World Neurosurgery
- Vol. 131, e23-e31
Genetic Profiles Related to Pathogenesis in Sporadic Intracranial Aneurysm Patients
- 1 November 2019
- Published by Elsevier in World Neurosurgery
- Vol. 131, e23-e31
Genetic Profiles Related to Pathogenesis in Sporadic Intracranial Aneurysm Patients
- Open Access
- 11 June 2019
- Published by Springer Nature in Chinese Neurosurgical Journal
- Vol. 5 (1) , 1-7
ACSS2-related autophagy has a dual impact on memory
Autophagy is an intracellular degenerative pathway which is responsible for neuronal survival. Under the condition of nutrient deprivation, autophagy can lead to dysfunction in memory consolidation. AMPK/mTOR pathway is currently the most studied autophagy mechanism, while recently researchers have proved ACSS2 can also affect autophagy. ACSS2 is phosphorylated at Ser659 by AMPK and then forms a translocation complex with Importin α5 to translocate into the nucleus. This process interacts with TFEB, resulting in upregulated expression of lysosomal and autophagosomal genes. These upregulations inhibit synaptic plasticity and hence memory functions. On the other hand, ACSS2 is also recognized as a regulator of histone acetylation. After recruiting CBP/p300 and activating CBP’s HAT activity in the nucleus, ACSS2 maintains the level of localized histone acetylation by recapturing acetate from histone deacetylation to reform acetyl-CoA, providing substrates for HAT. The increase of histone acetylation locally enhanced immediate early gene transcription, including Egr2, Fos, Nr2f2, Sgk1, and Arc, to benefit neuronal plasticity and memory in many ways.
- 11 June 2019
- Published by Springer Nature in Chinese Neurosurgical Journal
- Vol. 5 (1) , 1-7
Open AccessACSS2-related autophagy has a dual impact on memory
Autophagy is an intracellular degenerative pathway which is responsible for neuronal survival. Under the condition of nutrient deprivation, autophagy can lead to dysfunction in memory consolidation. AMPK/mTOR pathway is currently the most studied autophagy mechanism, while recently researchers have proved ACSS2 can also affect autophagy. ACSS2 is phosphorylated at Ser659 by AMPK and then forms a translocation complex with Importin α5 to translocate into the nucleus. This process interacts with TFEB, resulting in upregulated expression of lysosomal and autophagosomal genes. These upregulations inhibit synaptic plasticity and hence memory functions. On the other hand, ACSS2 is also recognized as a regulator of histone acetylation. After recruiting CBP/p300 and activating CBP’s HAT activity in the nucleus, ACSS2 maintains the level of localized histone acetylation by recapturing acetate from histone deacetylation to reform acetyl-CoA, providing substrates for HAT. The increase of histone acetylation locally enhanced immediate early gene transcription, including Egr2, Fos, Nr2f2, Sgk1, and Arc, to benefit neuronal plasticity and memory in many ways.
- Open Access
- 1 January 2019
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 10 (20) , 4793-4806
Glioblastoma Treatment Modalities besides Surgery
Glioblastoma multiforme (GBM) is commonly known as the most aggressive primary CNS tumor in adults. The mean survival of it is 14 to 15 months, following the standard therapy from surgery, chemotherapy, to radiotherapy. Efforts in recent decades have brought many novel therapies to light, however, with limitations. In this paper, authors reviewed current treatments for GBM besides surgery. In the past decades, only radiotherapy, temozolomide (TMZ), and tumor treating field (TTF) were approved by FDA. Though promising in preclinical experiments, therapeutic effects of other novel treatments including BNCT, anti-angiogenic therapy, immunotherapy, epigenetic therapy, oncolytic virus therapy, and gene therapy are still either uncertain or discouraging in clinical results. In this review, we went through current clinical trials, underlying causes, and future therapy designs to present neurosurgeons and researchers a sketch of this field.
- 1 January 2019
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 10 (20) , 4793-4806
Open AccessGlioblastoma Treatment Modalities besides Surgery
Glioblastoma multiforme (GBM) is commonly known as the most aggressive primary CNS tumor in adults. The mean survival of it is 14 to 15 months, following the standard therapy from surgery, chemotherapy, to radiotherapy. Efforts in recent decades have brought many novel therapies to light, however, with limitations. In this paper, authors reviewed current treatments for GBM besides surgery. In the past decades, only radiotherapy, temozolomide (TMZ), and tumor treating field (TTF) were approved by FDA. Though promising in preclinical experiments, therapeutic effects of other novel treatments including BNCT, anti-angiogenic therapy, immunotherapy, epigenetic therapy, oncolytic virus therapy, and gene therapy are still either uncertain or discouraging in clinical results. In this review, we went through current clinical trials, underlying causes, and future therapy designs to present neurosurgeons and researchers a sketch of this field.